NURECA · NSE
Nureca Limited
₹334.25
-2.44% (-₹8.35)
Prev. close
₹342.6
Volume
32,252
Delivery %
56.3%
As of
10 Aug 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Nureca Limited
Nureca Limited provides home healthcare and wellness products in India. The company offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeters, glucose meters, and thermometers, as well as connected products; orthopedic products, including massagers, pain management products, posture correctors, and rehabilitation products; and humidifiers and steamers, personal scales, yoga and exercise products, fitness tracking products, and dental and personal care products. It also provides mother and baby care products comprising baby feeding products, carry cots, baby skincare products, and bottle warmers and steamers; nutritional supplements and weight management products; and ECG products, fitness trackers, and smart weighing scales. In addition, the company provides orthopedic cushions, heating pads, and breast pumps. The company offers its products under the Dr Trust, Dr Physio, and Trumom brands. It markets its products through e-commerce platforms, distributors, retailers, and its websites. Nureca Limited was incorporated in 2016 and is based in Chandigarh, India.
Details
Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Saurabh Goyal
Headquarters
Chandigarh
Employees
154
Website
nureca.comExchange
View on NSE ↗Key stats
Market cap
₹335.95 Cr
P/E ratio (TTM)
74.5
EPS (TTM)
₹4.51
Beta (1Y · daily vs NIFTY 50)
1.21
Beta (5Y · monthly vs NIFTY 50)
1.82
Shares float
24.90 L
EPS · quarter ended Jun 2026
₹3.21
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹213.45 Cr | ₹255.55 Cr | ₹111.32 Cr | ₹91.93 Cr | ₹109.66 Cr | ₹146.96 Cr | |
| EBITDA | ₹64.36 Cr | ₹63.20 Cr | ₹-7.90 Cr | ₹30.70 L | ₹4.90 Cr | ₹8.28 Cr |
| ₹46.37 Cr | ₹44.96 Cr | ₹-8.25 Cr | ₹-1.79 Cr | ₹84.60 L | ₹2.08 Cr | |
| Diluted EPS | ₹62.04 | ₹44.96 | ₹-8.25 | ₹-1.79 | ₹0.85 | ₹2.11 |
Depreciation & amortisation has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹206.58 Cr | ₹205.17 Cr | ₹209.98 Cr | ₹196.16 Cr | |
| — | — | ₹3.33 Cr | ₹2.52 Cr | ₹4.97 Cr | ₹2.26 Cr | |
| Stockholders' equity | — | — | ₹194.88 Cr | ₹193.11 Cr | ₹194.29 Cr | ₹180.76 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹34.87 Cr | ₹1.40 Cr | ₹10.23 Cr | ₹-2.71 Cr | ₹-19.08 Cr | ₹3.30 Cr | |
| Investing cash flow | ₹-110.04 Cr | ₹-3.09 Cr | ₹-16.46 Cr | ₹17.58 Cr | ₹8.44 Cr | ₹14.49 Cr |
| ₹92.34 Cr | ₹-7.30 Cr | ₹-1.51 Cr | ₹-1.30 Cr | ₹-16.90 L | ₹-19.56 Cr | |
| Capital expenditure | — | ₹-6.00 Cr | ₹-39.60 L | ₹-1.09 Cr | ₹-4.32 Cr | ₹-6.83 Cr |
| End cash position | ₹17.24 Cr | ₹8.25 Cr | ₹50.40 L | ₹14.06 Cr | ₹3.24 Cr | ₹1.46 Cr |
Depreciation & amortization, Debt issued, Debt repaid, Capital expenditure have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Sep 22(5Q) | Dec 22–Jun 23(3Q) | Sep 23–Jun 24(4Q) | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25–Dec 25(2Q) | Jan 26–Jun 26(3Q) |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.00% | 62.98% | 63.24% | 63.77% | 64.06% | 64.30% | 64.33% | 64.97% | 68.09% |
| Public | 30.00% | 37.02% | 36.76% | 36.23% | 35.94% | 35.70% | 35.67% | 35.03% | 31.91% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Nureca Limited | ₹316.95 Cr | ₹334.25 | 70.0 | 1.75 | 1.2% | 0.01 | +34.0% | +39.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Nureca consolidated net profit rises 279.01% in the June 2026 quarter
Business Standard · 2 months ago